What is new in Acute Coronary Syndrome

Categories: EMA
Wishlist Share
Share Course
Page Link
Share On Social Media

About Course

This presentation provides an in-depth look at acute coronary syndrome (ACS), covering its definition, underlying mechanisms, diagnosis, and management strategies, including updates on antithrombotic therapy and revascularization. The discussion also addresses the importance of early diagnosis and intervention, as well as the challenges in implementing ideal treatment protocols. The content is designed to enhance understanding of ACS and improve clinical practice in the context of current guidelines.

What Will You Learn?

  • The definition of acute coronary syndrome and its spectrum, from unstable angina to ST-segment elevation myocardial infarction (STEMI).
  • The mechanistic basis of ACS, including the role of atherosclerotic plaque rupture and coronary thrombosis.
  • The universal definition of myocardial infarction (MI) based on clinical symptoms, ECG findings, and cardiac troponin levels.
  • How to classify ACS based on ECG findings: ST-segment elevation (STEMI), non-ST-segment elevation (NSTEMI), and unstable angina.
  • The importance of early recognition of both typical and atypical symptoms of ACS, including chest pain equivalents.
  • The interpretation of ECG findings in diagnosing ACS, with emphasis on ST-segment elevation, ST-segment depression, and new-onset left bundle branch block (LBBB).
  • The significance of "STEMI equivalents" such as LBBB, RBBB, and posterior MI.
  • The role of high-sensitivity cardiac troponin assays in diagnosing MI.
  • The management of ACS, including antithrombotic therapy, reperfusion strategies, and secondary prevention.
  • The role of fibrinolytic in STEMI management, especially when PCI is not immediately available, and the importance of pre-hospital administration.
  • The recommendations for timing of angiography and PCI in STEMI and NSTEMI patients.
  • The updated guidelines on antithrombotic therapy, particularly the use of dual antiplatelet therapy (DAPT) and its duration, and monotherapy options.
  • The importance of LDL management, beta-blocker therapy, and patient involvement in decision-making

Student Ratings & Reviews

No Review Yet
No Review Yet